Trial Profile
A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2013
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b/ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Dec 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 29 Dec 2011 New trial record